CFGI’s Capital Markets team assisted Ortho Clinical Diagnostics Holdings PLC (NASDAQ: OCDX) with their initial public offering. The offering priced 87.4 million ordinary shares at $17.00 per share for gross proceeds of $1.49 billion, before deducting underwriting discounts, commissions and offering expenses. The shares began trading on January 28, 2021, and the offering closed on February 1, 2021.
Ortho Clinical Diagnostics Holdings PLC (Ortho) is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions. Because Every Test is a Life™, Ortho never stops innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care. As a trusted partner of hospitals, hospital networks, blood banks and labs around the world, Ortho proudly serves the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs. Ortho is powered by Ortho Care™, a global, award-winning, holistic approach to service, which supports customers with best-in-class technical support, award-winning field support, and remote service and inventory support.
The CFGI team was led by April Coleman (Capital Markets) and Lindsi Scanlan (Accounting Advisory).
For further information on the offering, please read Ortho Clinical Diagnostics Holdings PLC’s press release.